Compare DMO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DMO | LUNG |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.9M | 97.1M |
| IPO Year | 2009 | 2020 |
| Metric | DMO | LUNG |
|---|---|---|
| Price | $9.77 | $1.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 45.6K | ★ 321.2K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $9.73 | $1.13 |
| 52 Week High | $12.08 | $2.89 |
| Indicator | DMO | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 22.69 | 47.86 |
| Support Level | N/A | $1.20 |
| Resistance Level | $11.20 | $2.16 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 7.05 | 32.26 |
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.